| Title |
Efinaconazole in the treatment of onychomycosis
|
|---|---|
| Published in |
Infection and Drug Resistance, June 2015
|
| DOI | 10.2147/idr.s69596 |
| Pubmed ID | |
| Authors |
Shari R Lipner, Richard K Scher |
| Abstract |
Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 63 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 21% |
| Student > Ph. D. Student | 6 | 10% |
| Student > Bachelor | 6 | 10% |
| Other | 4 | 6% |
| Student > Doctoral Student | 3 | 5% |
| Other | 11 | 17% |
| Unknown | 20 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 19% |
| Medicine and Dentistry | 11 | 17% |
| Nursing and Health Professions | 4 | 6% |
| Chemistry | 4 | 6% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 21 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2022.
All research outputs
#2,790,465
of 25,584,565 outputs
Outputs from Infection and Drug Resistance
#109
of 2,048 outputs
Outputs of similar age
#34,700
of 281,752 outputs
Outputs of similar age from Infection and Drug Resistance
#5
of 13 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,048 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.